|Articles|April 19, 2012

Integration of Mental Health and Substance Abuse Treatment

How would you rate the integration of mental health treatment with addiction treatment? Where is there room for improvement?

How would you rate the integration of mental health treatment with addiction treatment? Where is there room for improvement? We invite you to take the poll and submit your comments below.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

ByGrace Thetford-Harvey, MD,Tessa Manning, MD

December 2nd 2025

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

ByJon-Patrick Allem, PhD

November 27th 2025

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

ByMichèle Haykal, MD,Nidal Moukaddam, MD, PhD

November 19th 2025

Identifying and Treating High Functioning Substance Use Disorder

ByRachel Rohaidy, MD

November 10th 2025

TMS ketamine depression substance use disorder

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

BySteven R. Devore Best, MD

November 5th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Register now!

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Integration of Mental Health and Substance Abuse Treatment

Newsletter

Related Content

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

Identifying and Treating High Functioning Substance Use Disorder

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Southern Florida Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia

Transcranial Magnetic Stimulation in Sports Performance: Promise, Physiology, and Precaution

Semaglutide Potentially Protective Against Nephrotoxicity Caused by Lithium

Postoperative Delirium in Older Patients: Signs, Symptoms, Solutions

The Shirtless Football Coach, Dr Seuss, and Inspiring Leadership